New combo therapy offers hope for myeloma patients who stop responding to treatment
NCT ID NCT04661137
First seen Feb 11, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This study tests whether adding the drug selinexor to standard treatments (carfilzomib, daratumumab, or pomalidomide) can help people with multiple myeloma whose cancer has worsened on their current therapy. About 96 adults will receive the combination until their disease progresses or side effects become unmanageable. The main goal is to see how many patients achieve a partial or complete response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.